Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
643 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01928394 | A Study of Nivolumab by Itself or Nivolumab Combined With Ipilimumab in Patients With Advanced or Metastatic Solid Tumors | completed | Phase 1 / Phase 2 | 1,163 | Bristol-Myers SquibbINDUSTRY | 8 | Dec 27, 2024 | clinicaltrials |
| NCT03138512 | A Study Comparing Nivolumab, Nivolumab in Combination With Ipilimumab and Placebo in Participants With Localized Kidney Cancer Who Underwent Surgery to Remove Part of a Kidney(CheckMate 914) | completed | Phase 3 | 1,641 | Bristol-Myers SquibbINDUSTRY |
| 25 |
| Dec 18, 2024 |
| clinicaltrials |
| NCT06735781 | Clinical Outcomes of Patients With Resectable Non-Small Cell Lung Cancer Receiving Neoadjuvant Nivolumab Plus Chemotherapy in France | completed | — | 101 | Bristol-Myers SquibbINDUSTRY | 1 | Dec 16, 2024 | clinicaltrials |
| NCT06698887 | A Study to Evaluate the Long-Term Safety of Idecabtagene Vicleucel Treatment in Adults With Newly Diagnosed Multiple Myeloma in Korea | recruiting | — | 15 | Bristol-Myers SquibbINDUSTRY | 1 | Dec 13, 2024 | clinicaltrials |
| NCT04794010 | A Study in Participants With First-Line Nivolumab Plus Ipilimumb Therapy Combined With Two Cycles of Chemotherapy for Metastatic Non-Small Cell Lung Cancer(FINN) | active not recruiting | — | 825 | Bristol-Myers SquibbINDUSTRY | 1 | Dec 12, 2024 | clinicaltrials |
| NCT04340193 | A Study of Nivolumab and Ipilimumab and Nivolumab Alone in Combination With Trans-arterial ChemoEmbolization (TACE) in Participants With Intermediate Stage Liver Cancer(CheckMate 74W) | completed | Phase 3 | 26 | Bristol-Myers SquibbINDUSTRY | 19 | Nov 26, 2024 | clinicaltrials |
| NCT02613507 | Efficacy Study of Nivolumab Compared to Docetaxel in Subjects Previously Treated With Advanced or Metastatic Non Small Cell Lung Cancer(CheckMate 078) | completed | Phase 3 | 504 | Bristol-Myers SquibbINDUSTRY | 4 | Nov 19, 2024 | clinicaltrials |
| NCT03834662 | A Trial of AVID200, a Transforming Growth Factor β (TGFβ) Inhibitor, in Patients Malignancies | completed | Phase 1 | 19 | Bristol-Myers SquibbINDUSTRY | 2 | Nov 19, 2024 | clinicaltrials |
| NCT06073769 | A Post-Marketing Surveillance Study to Assess the Safety of Oral Azacitidine Maintenance Therapy in Korean Patients With Acute Myeloid Leukemia | recruiting | — | 154 | Bristol-Myers SquibbINDUSTRY | 1 | Nov 6, 2024 | clinicaltrials |
| NCT05298592 | A Study of BMS-986406 as Monotherapy and Combination Therapies in Participants With Advanced Tumors | completed | Phase 1 | 77 | Bristol-Myers SquibbINDUSTRY | 6 | Sep 26, 2024 | clinicaltrials |
| NCT05780736 | A Study to Evaluate Nivolumab in the Treatment of Early Stage Esophageal or Gastroesophageal Cancer(PROSPECT-ESO) | terminated | — | 33 | Bristol-Myers SquibbINDUSTRY | 2 | Sep 25, 2024 | clinicaltrials |
| NCT02815592 | Trial of BMS-986012 in Combination With Platinum and Etoposide | completed | Phase 1 | 12 | Bristol-Myers SquibbINDUSTRY | 1 | Sep 4, 2024 | clinicaltrials |
| NCT03668119 | A Study of Nivolumab Combined With Ipilimumab and Nivolumab Alone in Patients With Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)(CheckMate 848) | completed | Phase 2 | 212 | Bristol-Myers SquibbINDUSTRY | 17 | Aug 28, 2024 | clinicaltrials |
| NCT06160167 | Incidence of Hyperpigmentation in Black Patients With Multiple Myeloma Treated With Immunomodulatory Drugs | completed | — | 4,204 | Bristol-Myers SquibbINDUSTRY | 1 | Aug 23, 2024 | clinicaltrials |
| NCT03978611 | A Study to Assess Safety of Relatlimab With Ipilimumab in Participants With Advanced Melanoma Who Progressed on Anti-Programmed Cell Death Protein 1 (Anti-PD-1) Treatment | terminated | Phase 1 | 11 | Bristol-Myers SquibbINDUSTRY | 6 | Jul 24, 2024 | clinicaltrials |
| NCT03336216 | A Study of Cabiralizumab Given With Nivolumab With and Without Chemotherapy in Patients With Advanced Pancreatic Cancer | completed | Phase 2 | 205 | Bristol-Myers SquibbINDUSTRY | 11 | Jul 23, 2024 | clinicaltrials |
| NCT03195491 | A Study of Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Second-Line Nivolumab Monotherapy in Asia(CheckMate870) | completed | Phase 3 | 400 | Bristol-Myers SquibbINDUSTRY | 2 | Jul 18, 2024 | clinicaltrials |
| NCT02847728 | Pattern of Use and Safety/Effectiveness of Nivolumab in Routine Oncology Practice | completed | — | 1,189 | Bristol-Myers SquibbINDUSTRY | 14 | Jun 3, 2024 | clinicaltrials |
| NCT02899299 | Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma Patients(CheckMate743) | completed | Phase 3 | 605 | Bristol-Myers SquibbINDUSTRY | 21 | May 21, 2024 | clinicaltrials |
| NCT03001882 | An Exploratory Study of the Effects of Nivolumab Combined With Ipilimumab in Patients With Treatment-Naive Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)(CheckMate 592) | completed | Phase 2 | 230 | Bristol-Myers SquibbINDUSTRY | 8 | May 20, 2024 | clinicaltrials |
| NCT02910999 | Real-Life Study With Nivolumab (BMS-936558) in Advanced NSCLC Patients After Prior Chemotherapy(ENLARGE-Lung) | completed | — | 868 | Bristol-Myers SquibbINDUSTRY | 1 | May 13, 2024 | clinicaltrials |
| NCT01621490 | PH 1 Biomarker Study of Nivolumab and Ipilimumab and Nivolumab in Combination With Ipilimumab in Advanced Melanoma(PD-1) | completed | Phase 1 | 170 | Bristol-Myers SquibbINDUSTRY | 3 | Apr 23, 2024 | clinicaltrials |
| NCT06163170 | A Study to Evaluate Treatment With Nivolumab Alone and Nivolumab Combined With Ipilimumab in Children With Melanoma | completed | — | 100 | Bristol-Myers SquibbINDUSTRY | 1 | Apr 18, 2024 | clinicaltrials |
| NCT06169956 | An Observational Study to Evaluate Neoadjuvant Nivolumab (OPDIVO®) in Combination With Platinum-Based Chemotherapy in Non-Metastatic Non-Small Cell Lung Cancer Participants in Germany(NENI) | recruiting | — | 400 | Bristol-Myers SquibbINDUSTRY | 1 | Apr 18, 2024 | clinicaltrials |
| NCT05678283 | A Study of Absorption, Metabolism, and Elimination CC-90010 in Participants With Advanced Solid Tumors | withdrawn | Phase 1 | 0 | Bristol-Myers SquibbINDUSTRY | 1 | Apr 17, 2024 | clinicaltrials |
| NCT06361563 | Real-World Use of Adjuvant Nivolumab in Patients With Upper Gastrointestinal Cancer in Canada | completed | — | 250 | Bristol-Myers SquibbINDUSTRY | 1 | Apr 12, 2024 | clinicaltrials |
| NCT06361576 | Real-World Use of Nivolumab for the Treatment of Patients With Metastatic Upper Gastrointestinal Cancer in Canada | completed | — | 700 | Bristol-Myers SquibbINDUSTRY | 1 | Apr 12, 2024 | clinicaltrials |
| NCT06205290 | A Study to Compare the Efficacy and Safety of Lisocabtagene Maraleucel vs Investigator's Choice Options in Adult Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, Whose Disease Has Failed Treatment With Both BTKi and BCL2i Therapies | withdrawn | Phase 3 | 0 | Juno Therapeutics, Inc., a Bristol-Myers Squibb CompanyINDUSTRY | 11 | Apr 2, 2024 | clinicaltrials |
| NCT02247349 | BMS-986012 in Relapsed/Refractory SCLC | completed | Phase 1 / Phase 2 | 106 | Bristol-Myers SquibbINDUSTRY | 7 | Mar 5, 2024 | clinicaltrials |
| NCT04540705 | A Study to Compare Bempegaldesleukin (BEMPEG: NKTR-214) Combined With Nivolumab and Tyrosine Kinase Inhibitor (TKI) to Nivolumab and TKI Alone in Participants With Previously Untreated Kidney Cancer That is Advanced or Has Spread(PIVOT IO 011) | completed | Phase 1 | 30 | Bristol-Myers SquibbINDUSTRY | 8 | Feb 28, 2024 | clinicaltrials |
| NCT05005273 | A Study to Assess BMS-986207 in Combination With Nivolumab and Ipilimumab as First-line Treatment for Participants With Stage IV Non-Small Cell Lung Cancer | completed | Phase 2 | 1 | Bristol-Myers SquibbINDUSTRY | 12 | Feb 28, 2024 | clinicaltrials |
| NCT05498480 | Study of Relatlimab in Combination With Nivolumab in Chinese Participants(RELATIVITY-111) | completed | Phase 1 | 6 | Bristol-Myers SquibbINDUSTRY | 1 | Feb 20, 2024 | clinicaltrials |
| NCT03644498 | Study to Determine if the Flu Vaccine Increases the Risk of Muscle Damage in Participants Taking Drugs That Block Certain Proteins Made by Some Types of Immune System Cells | completed | — | 1,056 | Bristol-Myers SquibbINDUSTRY | 1 | Jan 18, 2024 | clinicaltrials |
| NCT05432622 | A Study of Treatment Patterns and Outcomes in Participants With Stage IIIA Melanoma Receiving Adjuvant Systemic Therapy | completed | — | 95 | Bristol-Myers SquibbINDUSTRY | 1 | Jan 18, 2024 | clinicaltrials |
| NCT03138499 | A Study of Nivolumab Plus Brentuximab Vedotin Versus Brentuximab Vedotin Alone in Patients With Advanced Stage Classical Hodgkin Lymphoma, Who Are Relapsed/ Refractory or Who Are Not Eligible for Autologous Stem Cell Transplant,(CheckMate 812) | terminated | Phase 3 | 23 | Bristol-Myers SquibbINDUSTRY | 3 | Jan 10, 2024 | clinicaltrials |
| NCT03157674 | Real-World Evidence and Treatment Patterns: Head and Neck Cancer | completed | — | 43,994 | Bristol-Myers SquibbINDUSTRY | 1 | Jan 5, 2024 | clinicaltrials |
| NCT01514864 | Trial of Dasatinib in Patients With Advanced Cancers Harboring DDR2 Mutation or Inactivating B-RAF Mutation | terminated | Phase 2 | 19 | Bristol-Myers SquibbINDUSTRY | 7 | Dec 19, 2023 | clinicaltrials |
| NCT02856438 | Early Patient Access Treatment Use Protocol CA204-220 | no longer available | — | — | Bristol-Myers SquibbINDUSTRY | 1 | Dec 19, 2023 | clinicaltrials |
| NCT04151563 | A Clinical Study Evaluating Nivolumab-containing Treatments in Patients With Advanced Non-small Cell Lung Cancer After Failing Previous PD-1/(L)1 Therapy and Chemotherapy(CheckMate 79X) | withdrawn | Phase 1 / Phase 2 | 0 | Bristol-Myers SquibbINDUSTRY | 10 | Dec 19, 2023 | clinicaltrials |
| NCT03980314 | A Study to Compare Nivolumab Drug Product Process D to Nivolumab Drug Product Process C in Participants With Stage IIIa/b/c/d or Stage IV Melanoma After Complete Resection | completed | Phase 1 | 261 | Bristol-Myers SquibbINDUSTRY | 14 | Dec 15, 2023 | clinicaltrials |
| NCT06154902 | Real-World Outcomes in Relapsed/Refractory Multiple Myeloma Patients Treated, or Eligible for Treatment, With Idecabtagene Vicleucel(ABE-DESCART) | active not recruiting | — | 350 | Bristol-Myers SquibbINDUSTRY | 1 | Dec 4, 2023 | clinicaltrials |
| NCT00355238 | A Phase II Open Label Study of BMS-582664 in Locally Advanced or Metastatic Hepatocellular Cancer | completed | Phase 2 | 137 | Bristol-Myers SquibbINDUSTRY | 8 | Dec 1, 2023 | clinicaltrials |
| NCT02368301 | Expanded Access Treatment Protocol CA204-143 | no longer available | — | — | Bristol-Myers SquibbINDUSTRY | 0 | Nov 30, 2023 | clinicaltrials |
| NCT02181738 | Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational)(CheckMate 205) | completed | Phase 2 | 294 | Bristol-Myers SquibbINDUSTRY | 10 | Nov 28, 2023 | clinicaltrials |
| NCT03414983 | An Investigational Immunotherapy Study of Nivolumab With Standard of Care Therapy vs Standard of Care Therapy for First-Line Treatment of Colorectal Cancer That Has Spread(CheckMate 9X8) | completed | Phase 2 / Phase 3 | 196 | Bristol-Myers SquibbINDUSTRY | 5 | Nov 18, 2023 | clinicaltrials |
| NCT02488759 | An Investigational Immuno-therapy Study to Investigate the Safety and Effectiveness of Nivolumab, and Nivolumab Combination Therapy in Virus-associated Tumors(CheckMate358) | completed | Phase 1 / Phase 2 | 578 | Bristol-Myers SquibbINDUSTRY | 11 | Nov 13, 2023 | clinicaltrials |
| NCT04825873 | A Study to Assess Safety of Nivolumab in Routine Oncology Practice in China | completed | — | 3,102 | Bristol-Myers SquibbINDUSTRY | 1 | Oct 13, 2023 | clinicaltrials |
| NCT02864251 | A Study of Nivolumab + Chemotherapy or Nivolumab + Ipilimumab Versus Chemotherapy in Non-Small Cell Lung Cancer (NSCLC) Participants With Epidermal Growth Factor Receptor (EGFR) Mutation Who Failed 1L or 2L EGFR Tyrosine Kinase Inhibitor (TKI) Therapy(CheckMate722) | completed | Phase 3 | 367 | Bristol-Myers SquibbINDUSTRY | 10 | Sep 28, 2023 | clinicaltrials |
| NCT02741570 | Study of Nivolumab in Combination With Ipilimumab Compared to the Standard of Care (Extreme Regimen) as First Line Treatment in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck(CheckMate 651) | completed | Phase 3 | 947 | Bristol-Myers SquibbINDUSTRY | 18 | Sep 21, 2023 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials